Alvotech Total Current Liabilities Over Time
ALVO Stock | USD 11.68 0.16 1.35% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alvotech Performance and Alvotech Correlation. Alvotech |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alvotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.85) | Revenue Per Share 1.283 | Quarterly Revenue Growth 43.997 | Return On Assets (0.08) |
The market value of Alvotech is measured differently than its book value, which is the value of Alvotech that is recorded on the company's balance sheet. Investors also form their own opinion of Alvotech's value that differs from its market value or its book value, called intrinsic value, which is Alvotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alvotech's market value can be influenced by many factors that don't directly affect Alvotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alvotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alvotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alvotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare Alvotech and related stocks such as Ikena Oncology, Eliem Therapeutics, and HCW Biologics Total Current Liabilities Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IKNA | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 24.3 M | 28.3 M | 27.2 M | 21.5 M | 14.2 M | 21.9 M |
HCWB | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1 M | 2.3 M | 3 M | 8.7 M | 9.2 M |
RNXT | 805 K | 805 K | 805 K | 805 K | 805 K | 805 K | 805 K | 805 K | 805 K | 805 K | 4.1 M | 938 K | 1.1 M | 1.2 M | 1.3 M |
TPST | 675 K | 675 K | 2.1 M | 5.8 M | 10.2 M | 11.2 M | 13.2 M | 7.8 M | 9.8 M | 12.5 M | 3.2 M | 20 M | 7.3 M | 9.4 M | 9.6 M |
SCPH | 2 M | 2 M | 2 M | 2 M | 2 M | 2 M | 3.7 M | 5.2 M | 6.7 M | 5.2 M | 9.3 M | 14.8 M | 7.4 M | 13.1 M | 8.3 M |
MIST | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 4.5 M | 8.3 M | 6.2 M | 6.8 M | 6.1 M | 7.2 M | 6.4 M |
MCRB | 178 K | 178 K | 178 K | 1.1 M | 5.1 M | 10.9 M | 30.5 M | 31.6 M | 42 M | 46 M | 46.4 M | 82.3 M | 85.6 M | 98.7 M | 103.6 M |
LUMO | 1.8 M | 10.7 M | 2.9 M | 3.9 M | 25.1 M | 14.8 M | 37.9 M | 22 M | 8.8 M | 11.8 M | 6.5 M | 5.1 M | 6.7 M | 7 M | 11.8 M |
Alvotech and related stocks such as Ikena Oncology, Eliem Therapeutics, and HCW Biologics Total Current Liabilities description
Total Current Liabilities is an item on Alvotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Alvotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
Check out Alvotech Performance and Alvotech Correlation. To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Alvotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.